Administration of lower doses of radium-224 to ankylosing spondylitis patients results in no evidence of significant overall detriment

Autor: David G. Hoel, Nicholas D. Priest, Lawrence T. Dauer
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Neoplasms
Radiation-Induced
Time Factors
Ankylosing Spondylitis
Cancer Treatment
030218 nuclear medicine & medical imaging
Hematologic Cancers and Related Disorders
0302 clinical medicine
Cause of Death
Epidemiology
Medicine and Health Sciences
Cause of death
Aged
80 and over
education.field_of_study
Osteosarcoma
Multidisciplinary
Leukemia
Incidence (epidemiology)
Thorium
Sarcomas
Radiotherapy Dosage
Hematology
Middle Aged
Chemistry
Oncology
030220 oncology & carcinogenesis
Injections
Intravenous
Physical Sciences
Medicine
Radium
Research Article
Chemical Elements
Adult
medicine.medical_specialty
Death Rates
Inflammatory Diseases
Science
Population
Immunology
Autoimmune Diseases
03 medical and health sciences
Safety-Based Drug Withdrawals
Chlorides
Population Metrics
Internal medicine
Leukemias
medicine
Humans
Spondylitis
Ankylosing
education
Spondylitis
Aged
Ankylosing spondylitis
Population Biology
Proportional hazards model
business.industry
Case-control study
Chemical Compounds
Cancers and Neoplasms
Biology and Life Sciences
Dose-Response Relationship
Radiation
medicine.disease
Case-Control Studies
Clinical Immunology
Clinical Medicine
business
Follow-Up Studies
Zdroj: PLoS ONE, Vol 15, Iss 4, p e0232597 (2020)
PLoS ONE
ISSN: 1932-6203
Popis: The use of low doses of radium-224 (224Ra) chloride for the treatment of ankylosing spondylitis was stopped following the discovery that patients treated with it had a higher than control incidence of leukaemia and other cancers. This was so even though the treatment resulted in decreased pain and increased mobility-both of which are associated with decreased mortality. It was decided to re-analyze the epidemiological data looking at all causes of death. The risk of leukaemia, solid cancer, death from non-cancer causes and from all causes in a study populations of men that received either the typical dose of 5.6 to 11.1 MBq of 224Ra, any dose of 224Ra or no radium were compared using the Cox proportional hazard model. For patients that received the typical dose of 224Ra agreed with the excess cancer was similar to that reported in previous studies. In contrast, these patients were less likely to die from non-cancer diseases and from all causes of death than the control patients. No excess mortality was also found in the population of all males that received the radionuclide. It is concluded that 224Ra treatment administered at low doses to patients with ankylosing spondylitis did not impact mortality from all causes. The study demonstrates the need to consider all causes of death and longevity when assessing health impacts following irradiation.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje